Sibofimloc

Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) [1][2].

Product Specifications

CAS Number

[1616113-45-1]

Product Name Alternative

Antibiotic-202

UNSPSC

12352005

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Antibiotic-202.html

Purity

99.70

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CC(N(CC1)CCC21C3=CC(C#C[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=CC=C3C5=CC=C(C#C[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)C=C52)=O

Molecular Formula

C35H39NO11

Molecular Weight

649.68

References & Citations

[1]Ramtohul, Yeeman K, et al. Preparation of mannose derivatives via coupling and click cycloaddition reactions for treating bacterial infections. From PCT Int. Appl. (2014), WO 2014100158 A1 20140626.|[2]W Reinisch, et al. P568 An open-label, multicenter, phase ib, pharmacokinetic (pk) and safety study of a fimh blocker, Sibofimloc (TAK-018/EB8018), in patients with Crohn’s disease (CD), Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020: S479–S480.